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A B S T R A C T
Alzheimer’s disease is a complex neurodegenerative disorder characterized by a multi-factorial etiology, not completely
understood to date. In this context, the application of metabolomics is emerging in the last years because of its potential
to monitor molecular alterations associated with disease pathogenesis and progression, as well as to discover candidate
diagnostic biomarkers. However, the huge heterogeneity and dynamism of the human metabolome makes impossible the
simultaneous determination of the entire set of metabolites from complex biological samples. Thus, the most common
strategy to get a comprehensive overview of the organism’s phenotypic expression is the combined use of complementary
metabolomic platforms. In this review, we summarize the advantages and limitations of the most important analytical
techniques usually employed in metabolomics, including nuclear magnetic resonance, direct infusion mass spectrometry
and hyphenated approaches based on the coupling of orthogonal separation mechanisms (i.e. liquid chromatography, gas
chromatography, capillary electrophoresis) with mass spectrometry. Moreover, the suitability of metabolomics to unravel
the complex pathology underlying to Alzheimer’s disease is also presented.
© 2016 Published by Elsevier Ltd.
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1. Introduction to Alzheimer’s disease
In the last decades, Alzheimer’s disease (AD) has become a ma-
jor challenge for the public health system due to the dramatically in-
crease of aged population worldwide. This neurodegenerative disor-
der, clinically defined by an insidious onset and a progressive loss
of memory and other cognitive functions, is the most prevalent form
of dementia among elderly people, accounting for 70% of total cases
[1]. This cognitive and functional decline is preceded by a pre-clin-
ical phase known as mild cognitive impairment (MCI), a complex
syndrome characterized by memory failures that may be considered
as an intermediate stage in the development of AD from normal ag-
ing [2]. The exact etiology of AD is still a huge puzzle to be solved
in which multiple players participate, including genetic, environmen-
tal, as well as ageing-related factors. In this sense, there is interna-
tional consensus about the multifactorial nature of this disorder, in-
volving numerous biochemical perturbations such as the deposition
of β-amyloid plaques (Aβ), hyperphosphorylation of tau protein, ox-
idative stress, inflammation, abnormal metal homeostasis, as well as
disruption in energetic and neurotransmitter pathways, among others
[3–6]. Furthermore it should be noted that, although AD has tradition-
ally been considered a primary neurodegenerative disorder that specif-
ically affects the central nervous system, there is growing evidence
that pathological processes associated with AD can also manifest in
the peripheral system [7].
Nowadays, diagnosis of AD can only be performed via exclusion
of other pathologies by using a combination of different neuropsy-
chological and laboratory tests [8]. However, definitive diagnosis re-
quires the post-mortem examination of the brain in order to confirm
the presence of Aβ plaques and neurofibrillary tangles. Furthermore,
this diagnostic protocol is only effective in patients with significant
cognitive decline, which impossibilities an early detection of AD and
reduces the efficacy of subsequent pharmacological treatments. Fi-
nally, it has been demonstrated that these criteria show low specificity
against other dementia (70%), with moderate sensitivity (80%) [9].
For all these reasons, the identification of new AD biomarkers is criti-
cal in order to monitor molecular mechanisms associated with disease
pathogenesis and progression, discover early and accurate diagnostic
tests, as well as for helping in the development of novel drug treat-
ments. To this end, the application of systems biology technologies,
and particularly metabolomics, is emerging in recent years because
of their potential to investigate biochemical alterations underlying to
pathological processes in a comprehensive manner.
2. The potential of metabolomics for the identification of disease
biomarkers
Metabolomics relies on the non-targeted characterization of the en-
tire set of metabolites from a biological sample. A major strength of
this approach is its potential to provide a global overview of multi-
ple biochemical pathways, reflecting changes downstream of the ge-
nomic, transcriptomic and proteomic levels [10]. In this context, it is
noteworthy that metabolites play a prominent role in systems biol-
ogy and the final phenotypic expression of the organism, which con-
fers to metabolomics a number of advantages over other traditional
omic-techniques such as genomics and proteomics, as summarized be-
low.
• Metabolites are the most reliable indicators of the organism’s phe-
notype, given that represent the end point of biochemical reactions,
directly reflecting the interactions between gene expression, proteins
function and the environment [10].
• Changes in metabolite concentrations are generally more pro-
nounced than those observed in other biological levels such as the
transcriptome or the proteome, making the detection of metabolite
profiles a relatively sensitive measure of biological status [11].
• Metabolic alterations are rapid indicators of abnormalities occurring
in the organism due to the high dynamism of metabolite homeosta-
sis [12].
• Metabolomic data can be directly translated across species because
most metabolic pathways are highly conserved through evolution,
which is crucial in order to inter-relate findings from experiments
with laboratory animals and human studies [13].
• Metabolomics is applicable to a variety of easily accessible biolog-
ical samples such as blood, urine or cerebrospinal fluid (CSF), with
reduced cost and analysis time, thus highlighting the clinical utility
of this approach [14].
Thus, metabolomics has been proven to be a suitable tool in bio-
medical research for the investigation of complex phenotypes affected
by genetic and environmental factors. Particularly, this holistic ap-
proach plays a pivotal role in the study of multifactorial disorders such
as Alzheimer’s disease, in which many heterogeneous processes are
involved. However, the great complexity of the human metabolome
considerably hinders the identification of these metabolic features
in a comprehensive manner. The human metabolome has not been
fully characterized yet, but recent estimates are over 40,000 annotated
compounds, according to the Human Metabolome Database (HMDB;
http://www.hmdb.ca) [15]. In this sense, it should be noted that the
metabolome comprises compounds from various origins. Endogenous
metabolites are synthetized and metabolized within the organism by
means of the action of enzymes involved in catabolic and anabolic
reactions. On the other hand, gut microflora also generates a great
number of compounds which can exhibit a large impact on health
and disease status. Finally, exogenous metabolites or xenobiotics are
imported into the organism from different sources (e.g. drugs, food,
pollutants), and then are usually bio-transformed in order to facili-
tate their excretion, thus generating a myriad of compounds detectable
in different biofluids and tissues. Another pitfall in metabolomics is
the great compositional diversity of the metabolome. Unlike genes,
transcripts and proteins, which are biopolymers that share the same
building blocks (four nucleotides for DNA/RNA; twenty amino acids
in the case of proteins), metabolites can be categorized into several
very different chemical classes, including lipids, carbohydrates, amino
acids, peptides, organic acids, and other many low molecular weight
(LMW) compounds, which results in a high variability of physico-
chemical properties [12]. Thereby, metabolic profiles are composed
of metabolites in a wide range of molecular weights, from 1 Da (pro-
ton) to 1500–2000 Da (complex lipids and small peptides); polari-
ties, including hydrophilic LMW-metabolites as well as hydrophobic
lipids; and volatilities, from low boiling point metabolites (e.g. breath
metabolites) to heavier compounds. Furthermore, metabolites are pre-
sent in biological samples in wide range of concentrations, which span
over several orders of magnitude (from molar to sub-picomolar), and
are subjected to a high temporal, spatial and inter-individual variabil-
ity depending on age, gender or diet, among other factors [12]. Conse-
quently, a great challenge of current metabolomic research is the de-
velopment of novel analytical approaches with the aim to maximize
metabolite coverage.
In recent years, numerous efforts have been made in order to in-
crease the capabilities of metabolomics for the identification of as
many metabolites as possible, with an especial focus on two comple-
mentary research lines: (i) development of algorithms and databases
for the annotation of metabolites; and (ii) optimization of orthogonal
analytical platforms to expand metabolomic coverage. The annotation
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imental data against metabolomic databases, but most of them are
still under development. Thus, the identification of “unknowns” is still
widely recognized as a major bottleneck in metabolomics. However,
this subject is out of the scope of the present work, so interested read-
ers can resort to a number of excellent recently published reviews
[16–18]. On the other hand, considering the great complexity of the
metabolome, it is clear that none analytical platform is able to deter-
mine the totality of metabolites present in a sample in a single analy-
sis. For this reason, the application of multiple complementary ap-
proaches has become the most common strategy with the aim to over-
come the analytical bias introduced by these individual techniques.
3. The application of metabolomics in Alzheimer’s disease
research
Alzheimer’s disease research has traditionally been hindered be-
cause of the long pre-symptomatic period of this neurodegenerative
disorder, the impossibility of studying microscopic changes until fi-
nal stages, as well as the complexity of etiology and the variability
of clinical symptoms. Furthermore, the lack of accurateness of current
diagnostic tests, especially at early stages of disease, may result in the
inclusion of pre-clinical AD patients within control groups in clini-
cal trials, thus limiting the reliability of discovered biomarkers [19].
Thereby, the use of metabolomics has emerged in recent years for the
investigation of pathological mechanisms underlying to this disorder
and the identification of novel biomarkers. In this context, numerous
authors have proposed the application of multiple metabolomic tech-
niques for studying AD pathogenesis, in both human cohorts and dif-
ferent mouse models (Table 1). With regards to these animal mod-
els, it should be noted that the most commonly employed are based
on the over-expression of mutated forms of the human amyloid pre-
cursor protein (APP), including the APPTg2576, APPV717F and CRND8
transgenic lines. On the other hand, some mouse models also co-ex-
press the mutated human presenilin 1 (PS1) in order to accelerate amy-
loid deposition, such as the APP × PS1 or the TASTPM double trans-
genic models. Moreover, various biological samples have been pre-
viously investigated with the aim to get a global overview of patho-
logical changes underlying to AD. Brain tissue analysis shows a great
potential since allows the in situ characterization of neuropathologi-
cal processes associated with AD. Alternatively, cerebrospinal fluid
(CSF) is an interesting biofluid given that its composition directly re-
flects the brain metabolic production. Finally, the use on non-invasive
samples, such as blood serum or plasma, urine and saliva, has also
been described with the aim to identify simpler and cheaper biomark-
ers translatable to the clinical practice. A comprehensive summary of
previous metabolomic studies in AD research will be provided in the
next sections of this review article, with a special focus on the limita-
tions and complementarities of employed analytical platforms.
3.1. High-throughput metabolomic approaches
3.1.1. Nuclear magnetic resonance
Nuclear magnetic resonance has played a prominent role in the
early beginnings of metabolomics because of its excellent robust-
ness, reproducibility and high-throughput capabilities. In this context,
the application of in vivo neuroimaging techniques based on mag-
netic resonance spectroscopy (MRS) could be considered as the first
metabolomic approximation to AD. This tool has successfully been
employed for the investigation of AD pathogenesis and its progres-
sion form MCI [20,21], as well as for the characterization of age re-
lated changes in various mouse models of this neurodegenerative dis
order [22,23]. Common metabolic features identified by in vivo MRS
include reduced brain levels of glutamate and glutamine, increased
myo-inositol content, which may be indicative of osmotic stress and
astrogliosis, as well as down-regulated N-acetyl-aspartate production,
a conventional marker of neural integrity. However, the low sensi-
tivity of this analytical approach considerably limits the number of
detectable metabolites, thus hindering its implementation in global
metabolomic studies.
On the other hand, in vitro NMR can be directly applied onto tis-
sue extracts and biofluids with improved sensitivity, thus enabling
the simultaneous identification of up to 100 metabolites. Similarly
to the previously described MRS-based investigations, numerous au-
thors proposed the application of this analytical platform to char-
acterize metabolic perturbations associated with AD in post-mortem
brain samples. In the 1990’s, several early studies were performed in
order to quantify the content of some important neurochemicals in
different brain regions and thus confirm previous findings obtained
by in vivo MRS [24–26]. More recently, a non-targeted NMR-based
metabolomic approach was employed to compare cortical metabolite
profiles from AD and amyotrophic lateral sclerosis (ALS) patients
[27]. In this line, Graham et al. also found significant metabolomic al-
terations in the neocortex region from demented patients, and demon-
strated that paired metabolites ratios could be more powerful tools
for discriminating AD patients from healthy control (HC) subjects
[28]. However, it should be noted that the use of post-mortem tissues
implies that disease is at its ending phase, which makes impossible
the investigation of disease pathogenesis and progression from early
stages. Alternatively, various transgenic animal models are also avail-
able for studying the neuropathology associated with AD, from which
brain samples can be obtained at different stages of disease. Dedeoglu
et al. compared in vivo MRS and in vitro NMR to investigate the dif-
ferences in the neurochemical profile between APPTg2576 transgenic
mice and wild type (WT) littermates, thus demonstrating that a wider
range of compounds can be measured by using high resolution spec-
troscopy (Fig. 1) [29]. Metabolomic analysis of cerebellum samples
from this animal model also showed significant alterations in levels
of important neurochemicals, such as N-acetyl-aspartate, γ-aminobu-
tyric acid or glutamate, among others [30]. On the other hand, Forster
et al. examined longitudinal metabolic changes in whole brain extracts
from TASTPM transgenic mice aged between 3 and 18 months, and
surprisingly did not find significant differences in N-acetyl-aspartate
levels [31]. Complementarily, other authors proposed the comparative
investigation of different brain areas in order to elucidate the regional
specificity of characteristic neuropathological mechanisms associated
with AD [32–34]. Thus, it has been demonstrated that hippocampus
and cortex are the most affected areas by AD-induced perturbations,
but significant metabolic impairments can also be observed in other
brain regions such as cerebellum, striatum and midbrain.
The analysis of biofluids is an interesting alternative to the use
of brain samples with the aim to discover potential diagnostic bio-
markers for their implementation in the clinical practice. In this con-
text, the application of NMR-based metabolomics to CSF samples has
demonstrated a great utility to discriminate between AD patients and
healthy controls because of its close similarity with the brain com-
position [35–37]. Alternatively, the use of peripheral samples also
shows a great potential for the development of non-invasive diagnos-
tic tests. In this sense, Graham et al. employed 1H NMR to com-
pare metabolomic alterations in brain and plasma samples from the
APP × PS1 mouse model [38]. Despite metabolites in plasma were
present in lower concentrations and were subjected to a higher vari-
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Table 1
Summary of metabolomic studies in Alzheimer’s disease research.
study population sample findings Ref.
Nuclear Magnetic Resonance
AD (N = 12), HC (N = 5) whole brain ↓N-acetyl-aspartate, γ-aminobutyric acid; ↑ glutamate [24]
AD (N = 13), HC (N = 4) temporoparietal cortex ↓N-acetyl-aspartate, creatine, γ-aminobutyric acid [25]
AD (N = 13), HC (N = 4) hippocampus, cerebellum ↓N-acetyl-aspartate, γ-aminobutyric acid [26]
AD (N = 8), ALS (N = 11) frontal cortex ↑alanine, acetate, glutamate, glutamine; ↓lactate, creatine [27]
AD (N = 15), HC (N = 15) neocortex ↑alanine, taurine [28]
APPTg2576 (N = 9), WT (N = 10) frontal cortex ↓N-acetyl-aspartate, glutamate, glutathione; ↑taurine [29]
APPTg2576 (N = 9), WT (N = 8) cerebellum ↑taurine, creatine, glutamate, N-acetyl-aspartate, γ-aminobutyric acid [30]
TASTPM (N = 7–8), WT
(N = 5-9)
whole brain ↑myo-inositol, choline, glycerophosphocholine; ↓succinate [31]
CRND8 (N = 5/5 young/old),






↓N-acetyl-aspartate, glutamate, glutamine, taurine, γ-aminobutyric acid, choline, phosphocholine, creatine,
phosphocreatine, succinate; ↑lactate, aspartate, glycine, alanine, leucine, isoleucine, valine, free fatty
acids
[32]





↓N-acetyl-aspartate; ↑myo-inositol, scyllo-inositol [33]
APPTg2576 (N = 39), WT (N = 44) frontal cortex, rhinal
cortex, hippocampus,
cerebellum, midbrain
↓glutamate, N-acetyl-aspartate, myo-inositol, phosphocholine, γ-aminobutyric acid; ↑creatine, taurine [34]
AD (N = 20), HC (N = 27) CSF specific resonances in AD (unidentified) [35]
AD (N = 10), HC (N = 34) CSF ↑creatinine [36]
AD (N = 76), EAD (N = 26),
MCI (N = 33), HC (N = 45)
CSF phenylalanine, glutamate, lactate, acetate, α-hydroxyisovalerate, α-hydroxybutyrate [37]
APP × PS1 (N = 6), WT (N = 6) whole brain, plasma brain: ↓N-acetyl-aspartata, γ-aminobutyric acid, creatine, ascorbic acid
plasma: ↓glutamate, glutamine, methionine, acetate, citrate
[38]
Aβ (N = 10), WT (N = 10) whole blood, plasma
hippocampus
whole blood: ↓niacinamide, hypoxanthine, citrate, lactate, pyruvate, creatine, choline, acetate, alanine,
phenylalanine, glycine, valine, tyrosine; ↑AMP
plasma: ↓citrate, pyruvate, creatine, phenylalanine, tyrosine, fatty acids, phospholipids glucose, formate,
glutamine
hippocampus: no significant differences
[39]
APP × PS1 (N = 27), WT
(N = 33)
plasma, liver plasma: ↑lipoproteins, triglycerides
liver: ↑unsaturated fatty acids, 3-hydroxybutyrate, aspartate, glutamine, uridine diphosphate, uridine
monophosphate, adenosine monophosphate; ↓alanine, lactate, betaine
[40]
SAMP8 (N = 5), SAMR1 (N = 5) serum ↓inosine, glucose, polyunsaturated fatty acids, choline, phosphocholine, HDL, LDL, 3-hydroxy-butyrate,
citrate, pyruvate; ↑lactate, saturated fatty acids, alanine, methionine, glutamine, VLDL
[41]
APPTg2576 (N = 3–5), WT
(N = 3–5)
urine ↑3-hydroxykynurenine, homogentisate, allantoin, acetate, trans-aconitate, tyrosine, hippurate, citrate,
urea; ↓trigonelline, 2-oxoglutarate, dimethylamine, trimethylamine, threonine, 1-methylnicotinamide
[42]
Direct MS Analysis
AD (N = 22), HC (N = 18) serum ↓PUFA-PCs; ↑SFA-PCs [45]
AD (N = 22), HC (N = 18) serum ↓PUFA-PLs, valine, glutamine, N-acetyl-glutamine, glutamate, histidine, arginine, dopamine, carnitine,
creatine; ↑SFA-PLs, free fatty acids, eicosanoids, triglycerides, choline, glycerophosphocholine, glucose
[46]
AD (N = 22), HC (N = 18) serum ↓PUFA-PLs, oleamide, histidine, arginine, imidazole, taurine, guanidine, putrescine; ↑eicosanoids,
diglycerides, kynurenine
[47]
AD (N = 19), HC (N = 17) serum ↓PUFA-PLs, LPLs, plasmalogens; ↑SFA-PLs [48]
AD (N = 30), HC (N = 30) serum ↓fatty acid amides, urea, creatine, malate, taurine, dopamine, serotonin, ↑ceramides, diglycerides, free
fatty acids, alanine, picolinic acid
[49]

















cortex, cerebellum ↓sulfatides [52]
AD (N = 6), HC (N = 8) superior frontal gyrus ↓sulfatides [53]
AD (N = 26), HC (N = 26) plasma ↓long-chain sphingomyelins; ↑ceramides [54]
AD (N = 34), MCI (N = 19), HC
(N = 28)




grey matter: ↓plasmalogens, phosphatidylethanolamines, docosahexaenoic acid; ↑monoglycerides,
diglycerides, VLCFA 26:0
white matter: ↓phosphatidylethanolamines, sulfatides; ↑monoglycerides, diglycerides
[55]
AD (N = 90), MCI (N = 77), HC
(N = 51)
serum ↓plasmalogens; ↑diglycerides [56]
AD (N = 50), HC (N = 50) CSF ↑sphingomyelins, phosphatidylcholines [57]
AD (N = 43), MCI (N = 33), HC
(N = 35)
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Table 1 (Continued)
study population sample findings Ref.
APP × PS1 (N = 30), WT
(N = 30)
serum ↓PUFA-PLs, LPLs, cholesteryl esters, free fatty acids, urea, serine, valine, threonine, pyroglutamate,
creatine, phosphoethanolamine, histidine, carnitine, glucose, tyrosine, tryptophan; ↑SFA-PLs,
eicosanoids, triglycerides, diglycerides, choline, GPE, inosine
[59]
APP × PS1 (N = 10), WT
(N = 10)
urine unidentified discriminant signals [60]





↓PUFA-PLs, acyl-carnitines, steroids, adenine, UMP, AMP, urea, aspartate, dopamine, tyrosine,
homocarnosine; ↑LPLs, PL(18:0/20:4), 22:5PLs, 22:4-PLs, propionyl-carnitine, free fatty acids,
eicosanoids, uracil, hypoxanthine, xanthine, FAPy-adenine, adenosine, inosine, acetate, propionate,
pyruvate, alanine, choline, valine, G3P, phosphocholine, N-acetyl-spermidine, GPC, GPI
[61]




alterations in the metabolism of phospholipids, fatty acids, acyl-carnitines, eicosanoids, acyl-glycerols,
steroids, amino acids, nucleotides, energy-related metabolites (changes depending on the tissue)
[62]
APP × PS1 (N = 8–9), WT
(N = 8–9)
brain, plasma longitudinal perturbations (6–18 months) in metabolism of phospholipids, amino acids, polyamines and
acyl-carnitines
[63]
APP × PS1×IL4 (N = 7),
APP × PS1 (N = 7), WT (N = 7)
serum ↓urea, histamine, threonine, aspartate, urocanic acid, dopamine, citrulline, tyrosine; ↑1-methyl-histamine,
eicosanoids
[64]
CRND8 (N = 6), WT (N = 6) hippocampus alterations in the homeostasis of arachidonic acid, glucose metabolism and fatty acid β-oxidation [65]
CRND8 (N = 6), WT (N = 6) cerebellum ↑eicosanoids, amino acids and derivatives, xanthosine, xanthine, urate; ↓inosine, guanosine [66]
Gas Chromatography–Mass Spectrometry
AD (N = 23), HC (N = 21) serum ↓valine, urea, aspartate, pyroglutamate, glutamine, phenylalanine, asparagine, ornithine, pipecolate,
histidine, tyrosine, palmitic acid, urate, tryptophan, stearic acid, cysteine; ↑lactate, α-ketoglutarate,
isocitrate, glucose, oleic acid, adenosine, cholesterol
[67]
AD (N = 24), MCI (N = 16), PD
(N = 22), HC (N = 8)
exhaled breath ↑phenol (PD) [68]





changes in 55 metabolites, including energy related metabolites (glucose metabolism, TCA), amino acids,
nucleosides, and others
[69]
SAMP8 (N = 5, 2 months; N = 6,
7 months; N = 7, 12 months)
hippocampus ↑cholesterol, oleic acid, phosphoglyceride, N-acetyl-aspartate; ↓alanine, serine, glycine, aspartate,
glutamate, γ-aminobutyric acid, malic acid, butanedioic acid, fumaric acid, citric acid, pyroglutamic acid,
urea, lactic acid
[70]
TASTPM (N = 16), WT (N = 5) whole brain, plasma brain: ↑D-fructose, valine, serine, threonine; ↑zymosterol
plasma: ↑D-glucose, D-galactose, linoleica cid, arachidonic acid, palmitic acid, gluconic acid
[71]
APPTg2576 (N = 15), WT (N = 17)
CRND8 (N = 9), WT (N = 9)
APPV717I (N = 10), WT (N = 12)
urine ↑phenylacetone; ↓3-methylcyclopentanone, 4-methyl-6-hepten-3-one, 6-hydroxy-6-methyl-3-heptanone [72]
CHO-AβPP695 (N = 12, 12 h;
N = 10, 24 h) CHO-WT
(N = 12, 12 h; N = 10, 24 h)
culture media ↑D-glucose, malonate, methyl-malonate, citrate, 2-oxoglutarate, serine, cystine; ↓succinate, pyruvate,
lysine, alanine, proline, ornithine, isoleucine glycine, tryptophan, threonine, leucine, uracil, glycerol
[73]
Reversed-Phase Liquid Chromatography Mass Spectrometry (Hydrophobic metabolites)
AD (N = 10), HC (N = 10) plasma ↓demosterol [74]
APOE2 (N = 6), APOE3 (N = 6),
APOE4 (N = 6)
plasma, whole brain alterations in phospholipids, sphingolipids, cholesterol and triglycerides [75]
APP × PS1,
APP × PS1 × MAGL−/−,
MAGL−/−, WT (N = 4–8)
whole brain APP × PS1: ↑monoglycerides, N-acylethanolamines, free fatty acids, eicosanoids, phosphatidic acids,
lysophosphatidylcholines, cholesteryl esters
APP × PS1 × MAGL−/−: ↑arachidonoyl-glycerol; ↓arachidonic acid, prostaglandins, thromboxane 2
[76]
AD (N = 16), MCI (N = 12), HC
(N = 10)
plasma ↑1-(9E-hexadecenoyl)-sn-glycero-3-phosphocholine, D-glucosaminide, glycocholic acid,
glycodeoxycholic acid, glycochenodeoxycholic acid
[77]
AD (N = 20), HC (N = 20) plasma ↓lysophosphatidylcholines, tryptophan, phytosphingosine, dihydrosphingosine, hexadecasphinganine [78]
AD (N = 36), MCI (N = 48), HC
(N = 40)
plasma ↓long chain cholesteryl esters [79]
AD/MCI (N = 35), Converters
(N = 18), HC (N = 53)
plasma ↓phosphatidylcholines, lyso-phospholipids, serotonin, phenylalanine, proline, lysine, taurine, acyl-
carnitines, malate; ↑glycoursodeoxycholic acid, proline-asparagine
[80]
AD (N = 75), MCI (N = 17), HC
(N = 45)
serum ↓PUFA-PLs, PUFA-SMs, sulfatides, monoglycerides, oleamide, histidine pregnenolone sulfate; ↑SFA-
PLs, SFA-SMs, ceramides, acyl-carnitines, phenyl-acetyl-glutamine
[81]
AD (N = 660), MCI (N = 583) serum ↑sphinganine-1-phosphate, 7-ketocholesterol, 3-methoxytyrosine, deoxyribose-5-phosphate, p-
phenyllactic acid, lyso-phosphatidylcholine; ↓phenylalanine, ornithine, glutamate
[82]
AD (N = 256), HC (N = 218) saliva ↑sphinganine-1-phosphate, ornithine, p-phenyllactic acid; ↓inosine, 3-dehydrocarnitine, hypoxanthine [83]
AD (N = 660), MCI (N = 583) saliva ↑cytidine, sphinganine-1-phosphate, ornithine, p-phenyllactic acid, pyroglutamate, glutamate, tryptophan;
↓inosine, 3-dehydrocarnitine, hypoxanthine
[84]
AD (N = 46), HC (N = 37) serum, urine serum: ↑palmitic amide, monoiodothyronine, antrimethyltridecanoic acid, PGE2α dimethyl amine, (6R)-
vitamin D3 6,19- (4-phenyl-1,2, 4-triazoline-3,5-dione); ↓1-methylinosine, 16-bromo-9-hexadecenoic
acid, lysophosphatidylcholines, dihydrosphingosine, N-acetyl-glutamine, 1α,25-dihydroxy-2α-
(3-hydroxypropoxy) vitamin D3
urine: ↑N-acryloylglycine, argininosuccinic acid, dethiobiotin, isobutyryl-L-carnitine,
2-hydroxy-N-(2-hydroxyethyl)-N,N-dimethyl-1-dodecanaminium, L-aspartyl-4-phosphate, L-glutamine,
5-L-glutamylglycine, azelaic acid, aminopterin, cytidine; ↓acetyl-carnitine,
estra-1,3,5(10),7-tetraene-3,17α-diol, p-cresol glucuronide, etiocholanolone glucuronide
[85]
AD (N = 10), HC (N = 10) frontal lobe, parietal lobe,
occipital lobe
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Table 1 (Continued)
study population sample findings Ref.
APP/tau (N = 5, 4 months), APP/
tau (N = 5, 10 months), APP/tau
(N = 3, 15 months), WT (N = 5)
whole brain, plasma brain: ↑cholesteryl esters, 17,18-diHETE, 19,20-diHDoPE; ↓PUFA-PLs, plasmalogens, sphingomyelins,
triglycerides, eicosanoids
plasma: ↑phospholipids, sphingomyelins, triglycerides, cholesteryl esters, eicosanoids
[87]
Sco (N = 10), Sco + HA
(N = 10), Sco + LP (N = 10),
Sco + HA + LP (N = 10), WT
(N = 10)
whole brain ↑tyrosine, arginine, lyso-phosphatidylcholine-20:5, PI(16:2)/(16:1)/(16:0), S-adenosylhomocysteine,; ↓γ-
glutamylcysteine, N-acetylcysteine, DG(18:4)/(18:3)/(14:1), choline, taurine
[88]
Aβ (N = 6), Aβ+Donezepil
(N = 6), Aβ+TG (N = 6, low-
medium-high doses), WT
(N = 10)
plasma ↑proline, valine, tryptophan, lyso-phosphatidylcholines; ↓acyl-carnitines, phytosphingosine, N-
eicosanoylethanolamine, fatty acids
[89]
APP × PS1 (N = 10),
APP × PS1 + G-Rg1 (N = 10),
APP × PS1 + G-Rg2 (N = 10),
WT (N = 10)
whole brain ↑hypoxanthine; ↓phytosphingosine, dihydrosphingosine, hexadecasphinganine, lyso-
phosphatidylcholines
[90]
Aβ (N = 10), Aβ+G-Rg1
(N = 10, low-medium-high
doses), Aβ+G-Rb1 (N = 10,
low-medium-high doses), WT
(N = 10), WT + saline (N = 10)
plasma ↑phenylalanine; ↓lyso-phosphatidylcholines, tryptophan, dihydrosphingosine [91]
D-Gal/Al (N = 10), D-Gal/
Al + KXS (N = 10 low-
medium-high doses), WT
(N = 10)
serum ↑lysine, allantoic acid, 5′-deoxyadenosine, N6-acetyl-L-lysine, GPC, 5-L-glutamyl-taurine, bile acids,
deoxyribose-5-phosphate, eicosanoids, hydrox-fatty acids, anserine, ubiquinone-1, QH2, arachidonic
acid, sulfatide; ↓uridine, leucine formylanthranilate, adenine, 4-imidazolone-5-propionic acid,
homovanillin, oxo-fatty acids, epimelibiose, 3,4-dihydroxyphenylacetaldehyde, sphingosine,
phytosphingosine, adrenoyl ethanolamide, fatty acids
[92]
Reversed-Phase Liquid Chromatography Mass Spectrometry (Hydrophilic metabolites)
AD (N = 17), HC (N = 17) CSF 53 unidentified discriminant signals [93]
AD I–II (N = 7), AD III–IV
(N = 4), AD V–VI (N = 5), HC
(N = 4)
entorhinal cortex ↓dGMP, glycine, xanthosine, inosine diphosphate, deoxyguanosine; ↑guanine [94]
AD (N = 15), HC (N = 15) CSF ↓norepinephrine, α-tocopherols, 3-methoxytyramine, ascorbate; ↑5-hydroxytryptophan, methoxy-
hydroxyphenyl glycol
[95]
AD (N = 40), MCI (N = 36), HC
(N = 38)
CSF ↑methionine, 5-hydroxyindoleacetic acid, vanillylmandelic acid, xanthosine, glutathione, hypoxanthine [96]
AD (N = 4 young), AD (N = 4
old), HC (N = 3)
frontal lobe ↓L-phenylalanine; ↑L-lactate [97]
MCI (N = 20), HC (N = 20) saliva ↓taurine, peptides, 1,8-diazacyclotetradecane-2,9-dione, 4-(hydroxylamino)-N,N-dimethylaniline;
↑2-amino-heptanoic acid/L-alanine-n-butyl ester/N-methyl-isoleucine
[98]
CRND8 (N = 12), WT (N = 12) urine ↑methionine, desaminotyrosine, phenylacetylglycine, dihydrouracil, ureidopropionic acid, thiocysteine;
↓choline, taurine, N1-acetyl-spermidine, 5-hydroxy-indoleacetic acid, hydroxyphenylglycine
[99]
Hydrophilic Interaction Liquid Chromatography Mass Spectrometry
AD (N = 15), HC (N = 15) neocortex 76 unidentified discriminant signals [100]
AD (N = 20), HC (N = 20) plasma 54 unidentified discriminant signals [101]
MCI_AD (N = 19), MCI
(N = 16), HC (N = 37)
plasma ↓4-amino-butanal, γ-aminobutyric acid, ornithine, N-acetyl-putrescine; ↑creatine, arginine,
methylthioadenosine, N-acetyl-spermidine, N-diacetyl-spermine, putrescine, spermidine, spermine
[102]
CRND8 (N = 18/12, 12/18
weeks), WT (N = 12/12, 12/18
weeks)
urine 55 differential metabolites involved in the homeostasis of amino acids (e.g. tryptophan, tyrosine,
phenylalanine, lysine), fatty acids, purines and pyrimidines, ascorbate, and others
[103]
Capillary Electrophoresis Mass Spectrometry
AD (N = 23), MCI_AD (N = 9),
MCI_stable (N = 22), SCI
(N = 19)
CSF ↑choline, valine, tripeptide, dimethylarginine, creatine, serine; ↓arginine, suberylglycine, carnitine,
histidine
[104]
AD (N = 42), MCI (N = 14), HC
(N = 37)
serum ↑choline, creatinine, dimethylarginine, homocysteinyl-cysteine, acyl-carnitines, peptides; ↓creatine,
asparagine, methionine, histidine, carnitine, N-acetyl-spermidine, valeryl-carnitine
[105]
AD (N = 3), FTLD (N = 4), LBD
(N = 3), HC (N = 9)
serum, saliva serum: ↑β-alanine, creatinine, hydroxyproline, glutamine, isocitrate, cytidine
saliva: ↓arginine, tyrosine
[106]
Reversed-Phase Liquid Chromatography/Gas Chromatography Mass Spectrometry
AD (N = 47), MCI (N = 143),
HC (N = 46)
serum baseline: ↓plasmalogens, phosphatidylcholines, sphingomyelins, sterols; ↑histamine
progression: ↑2,4-dihydroxybutanoic acid
[107]
AD (N = 57), MCI (N = 58), HC
(N = 57)
plasma ↓fatty acids, dimethylglycine, glutamate, uridine, glyceraldehyde, butanedioic acid, 2-butenedioic acid,
5-oxoproline, taurine, hypotaurine, malate; ↑glutamine, 2-aminoadipic acid, proline, cysteine, cytidine,
thymine, hypoxanthine, carbohydrates, citrate
[108]
AD (N = 79), HC (N = 51) CSF ↑cysteine, tyrosine, phenylalanine, methionine, serine, pyruvate, taurine, creatinine,
cortisol, dopamine; ↓uridine
[109]
AD (N = 40), HC (N = 38) CSF 2 unidentified discriminant signals [110]
APP × PS1 (N = 30), WT
(N = 30)
serum alterations in the metabolism of phospholipids, sphingolipids, fatty acids, cholesterol and bile acids,
energy-related metabolites and amino acids
[111]
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Table 1 (Continued)
study population sample findings Ref.
APP × PS1 (N = 30), WT
(N = 30)
liver, kidney alterations in the metabolism of phospholipids, sphingolipids, fatty acids, acyl-carnitines, cholesterol and
bile acids, energy-related metabolites and amino acids
[113]
APP × PS1 (N = 30), WT
(N = 30)
spleen, thymus alterations in the metabolism of phospholipids, sphingolipids, fatty acids, acyl-carnitines, energy-related
metabolites, amino acids and purines
[114]
APPTg2576 (N = 3), PS1 (N = 3),
APP × PS1 (N = 6), WT (N = 6)
hippocampus alterations in nucleotide, TCA cycle, energy transfer, carbohydrate, neurotransmitter and amino acid
metabolic pathways
[115]
Reversed-Phase/Hydrophilic Liquid Chromatography Mass Spectrometry
AD (N = 21), MCI_AD (N = 12),
MCI_stable (N = 21), HC
(N = 21)
CSF changes in levels of uracil, xanthine, uridine, tyrosyl-serine, methylsalsolinol, nonanoylglycine,
dopamine-quinone, caproic acid,vanylglycol, histidine, pipecolic acid, hydroxyphophinyl-piruvate,
creatinine, taurine, C16-sphingosine-1-phosphate, tryptophan, 5′-methylthioadenosine
[116]
AD (N = 30), MCI (N = 30), HC
(N = 30)
plasma ↓sphingomyelins [117]
AD (N = 15), MCI (N = 15), HC
(N = 15)
plasma, CSF changes in more than 150 metabolites (amino acids, energy-related metabolites, lipids, neurotransmitters) [118]
AD (N = 21), HC (N = 19) frontal cortex alterations in the metabolism of phospholipids and six metabolic pathways of the central metabolism:
Alanine, Aspartate, and Glutamate Metabolism; Arginine and Proline Metabolism; Cysteine and
Methionine Metabolism; Glycine, Serine, and Threonine Metabolism; Purine Metabolism; Pantothenate
and CoA Biosynthesis
[119]
Abbreviations: Aβ, amyloid-β; AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; AMP, adenosine monophosphate; APOE, apolipoprotein E; APP, amyloid precursor
protein; CHO, Chinese hamster ovary; CSF, cerebrospinal fluid; DG, diglyceride; D-Gal, D-galactose; dGMP, deoxyguanosine monophosphate; diHDoPE,
dihydroxy-docosapentaenoic acid; diHETE, dihydroxy-eicosatetraenoic acid; EAD, early Alzheimer’s disease; FTLD, frontotemporal lobe dementia; G-Rb1, gindenoside Rb1;
G-Rg1, gindenoside Rg1; G3P, glycerol-3-phosphate; GPC, glycerophosphocholine; GPE, glycerophosphoethanolamine; GPI, glycerophosphoinositol; HA, huperzine A; HC,
healthy control; HDL, high density lipoprotein; IL4, interleukin 4; KXS, Kai-Xin-San; LBD, Lewy body disease; LDL, low density lipoprotein; LP, ligustrazine phosphate; LPL,
lyso-phospholipid; MAGL, monoacylglycerol lipase; MCI, mild cognitive impairment; PC, phosphatidylcholine; PD, Parkinson’s disease; PI, phosphatidylinositol; PL, phospholipid;
PS1, presenilin 1; PUFA, polyunsaturated fatty acid; SAMP8, senescence accelerated mouse-prone 8; SAMR1, senescence accelerated mouse-resistant 1; SCI, subjective cognitive
impairment; Sco, scopolamine; SFA, saturated fatty acid; SM, sphingomyelin; TCA, tricarboxylic acid cycle; TG, total gingenosides; UMP, uridine monophosphate; VLCFA, very
long chain fatty acid; VLDL, very low density lipoprotein; WT, wild type.
accurate classification models, thus evidencing the utility of non-in-
vasive biological samples for studying pathological alterations under-
lying to this neurodegenerative disorder. Similarly, blood and hip-
pocampus extracts from a mouse model produced by intracerebroven-
tricular infusion of Aβ peptides were examined in order to identify
metabolic changes associated with the induction of neuroinflamma-
tory processes [39]. Numerous perturbations were observed in blood
levels of various metabolites involved in energy metabolism, but sur-
prisingly no significant differences were detected in hippocampal
metabolomic profiles. Furthermore, it is noteworthy that levels of
these disrupted metabolites were normalized after treatment with gal-
lic acid, a bioactive compound with anti-inflammatory properties,
which supports that neuroinflammation is a primary trigger of Aβ-in-
duced metabolomic alterations. In a more recent study, plasma and
liver samples from APP × PS1 transgenic mice were subjected to
NMR-based metabolomics in order to elucidate the possible involve-
ment of peripheral organs in AD pathogenesis [40]. Significant
changes were observed in levels of lipids, nucleotides and energy-re-
lated metabolites, thus demonstrating the occurrence of oxidative
stress and impaired energy metabolism at systemic levels. Jiang et al.
also found significant metabolic impairments in serum samples from
the senescence accelerated mouse-prone 8 (SAMP8), which could be
indicative of an abnormal homeostasis of glucose and lipids, as well as
an attenuated protective function of inosine [41]. Finally, it should be
noted that urine samples can also provide valuable information in AD
research. In this context, Fukuhara et al. recorded 1H NMR spectra of
urine samples from APPTg2576 transgenic mice aged between 4 and 15
months, which revealed significant metabolomic alterations indicative
of oxidative stress in the onset of disease [42].
Accordingly, it could be concluded that NMR-based platforms ex-
hibit a great potential for high-throughput metabolomics, which al-
lows the simultaneous determination of various very important neu-
rochemicals closely related to the pathogenesis of AD and other neu-
rodegenerative disorders, including N-acetyl-aspartate, myo-inositol,
glutamate, γ-aminobutyric acid and taurine, among others. However,
a major drawback of this metabolomic approach is its low sensitivity,
which considerably limits the number of measurable metabolites, as
shown in Table 1.
3.1.2. Direct infusion/flow injection—mass spectrometry
Similarly to NMR, metabolomics based on direct infusion or flow
injection of crude extracts into a mass spectrometer can be used for
high-throughput fingerprinting of samples in short times. However, it
should be noted that MS is much more sensitive and selective than
NMR, thus enabling the simultaneous determination of a wider range
of metabolites in biological samples (Fig. 2). Thereby, since the pub-
lication of the first works describing the application of direct mass
spectrometry analysis in metabolomics [43], numerous authors have
demonstrated the potential of this technique as a suitable tool for fast
and comprehensive metabolomic screening [44]. Due to the ion sup-
pression caused by the direct introduction of whole samples into the
ionization source, the most important findings in the majority of pre-
viously published DIMS-based studies in AD research are mainly as-
sociated with abnormalities in high-abundance lipids (Table 1). In
this context, González-Domínguez et al. described the application of
a metabolomic strategy based on a two-step sample treatment and
DI-ESI–MS analysis for serum fingerprinting [45,46]. In order to ob-
tain comprehensive metabolic profiles, serum samples were subjected
to protein precipitation with organic solvents to get methanolic ex-
tracts containing polar metabolites, and then protein precipitates were
again extracted to recover lipophilic compounds (Fig. 2). Notably,
significant alterations were observed in circulating levels of differ-
ent phospholipid (PL) classes, principally phosphatidylcholines (PC),
with reduced content of species containing polyunsaturated fatty acids
(PUFA) and increased levels of the corresponding saturated fatty acid
(SFA)-derived lipids, which could be indicative of neural membrane
breakdown processes. However, changes in other LMW metabolites
were also detected, evidencing impairments in energy metabolism and
neurotransmission, as well as the induction of oxidative stress in AD
patients. Complementarily, serum samples from this cohort of pa-
tients were also examined using a lipidomic approach based on the
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Fig. 1. Representative MRS (a) and NMR spectra (b) of cortex samples obtained from
transgenic mice (APP) and wild type littermates (WT). Reprinted from Dedeoglu et al.
[29] with permission from Elsevier.
method and subsequent analysis by DIMS [47]. Thereby, a large
number of metabolites could be fingerprinted, including some neutral
lipids not easily detectable by conventional metabolomic approaches,
such as di- and triglycerides or cholesterol derivatives, among others.
Besides a reduced content of PUFA-PLs, authors also observed a sig-
nificant over-production of diglycerides, the final by-product of phos-
pholipid hydrolysis via the action of phopholipases C and D. Taking
into account the huge evidence about the involvement of an abnor-
mal metabolism of membrane lipids in AD pathogenesis, an analytical
multi-platform was developed for performing a comprehensive char-
acterization of the phospholipidome in order to get new insights about
these disturbances [48]. For this, after DIMS-based metabolomics,
serum phospholipids were profiled by RP-UHPLC coupled to ele-
mental (inductively coupled plasma mass spectrometry) and molec-
ular (quadrupole-time of flight) mass spectrometry. Thereby, it was
demonstrated that impairments observed in phospholipid metabolism
could have a multifactorial origin, involving different pathological
processes such as the over-activation of phospholipases, imbalances
in the levels of PUFA/SFA, oxidative stress or peroxysomal dys-
function, among others. In a more recent study, González-Domínguez
et al. optimized a metabolomic platform based on flow injection in
an APPI-MS system [49]. The APPI source provides complemen-
tary ionization capabilities to conventional ESI,
thus allowing the simultaneous analysis of polar and non-polar com-
pounds. The application of this analytical procedure to serum samples
from AD patients revealed significant changes in levels of different
lipid classes and other metabolites implicated in different neurotrans-
mission systems. An interesting alternative to conventional DIMS
for the comprehensive characterization of lipid alterations associated
with AD is the multi-dimensional mass spectrometry-based shotgun
lipidomic (MDMS-SL) platform. Numerous studies described the ap-
plication of this strategy in plasma and brain samples, from both hu-
man patients and mouse models, thus evidencing significant pertur-
bations in the homeostasis of plasmalogens [50], sulfatides [51–53],
ceramides [51,54] and sphingomyelins [54]. More recently, Wood
et al. used a novel lipidomic approach based on the extraction of
lipids from CSF, brain and serum samples with a mixture of
tert-butyl-methylether and methanol, and subsequent fingerprinting by
ESI-Orbitrap-MS in order to investigate lipidomic alterations along
the progression of AD from MCI [55,56]. In line with previous stud-
ies, significant changes were observed in levels of plasmalogens,
phosphatidylethanolamines and diglycerides, among other com-
pounds. Alternatively, other authors have proposed the use of tar-
geted metabolomics based on the AbsoluteIDQ™ kit developed by
Biocrates Life Sciences AG (Innsbruck, Austria), which allows the
simultaneous quantification of endogenous metabolites from six dif-
ferent compound classes, including acyl-carnitines, amino acids, hex-
oses, phospholipids, sphingolipids and biogenic amines [57,58].
Direct MS analysis has also demonstrated a great utility for the
investigation of AD-like pathology in different transgenic models.
In this context, it should be noted the metabolomic multi-compart-
mental characterization of the APP × PS1 mouse model accomplished
by González-Domínguez et al. in recent years. The combination of
the previously described DI-ESI–MS and FI-APPI-MS methodologies
enabled the identification of numerous disturbed pathways in serum
samples from these mice, including perturbed phospholipid homeosta-
sis, energy-related failures and oxidative stress, among others [59].
These findings are in agreement with earlier studies performed in
cohorts of AD patients and healthy control subjects, thus confirm-
ing the potential of these transgenic mice to model this neurodegen-
erative disorder. In another work, the DIMS platform optimized for
high-throughput serum fingerprinting was adapted for the analysis of
urine samples because of the great interest of this biofluid in the clin-
ical practice [60]. In order to minimize ion suppression caused by
the high salt content of this matrix and to correct the inherent in-
ter-individual variability, multiple sample preparation procedures and
normalization strategies were assayed. Then, the optimized approach
based on DIMS analysis of diluted urines and subsequent statistical
data normalization was used to discriminate between APP × PS1 and
WT mice. Various brain tissues were also examined by DIMS-based
metabolomics in order to carry out an in situ investigation of neu-
ropathological mechanisms related to AD pathogenesis and determine
the regional specificity of these alterations [61]. Major differences
were detected in cortex and hippocampus, but cerebellum and olfac-
tory bulbs were also perturbed to a lesser extent. Finally, other periph-
eral organs were also analyzed in order to evaluate the systemic na-
ture of this neurodegenerative disorder, including the liver, kidneys,
spleen and thymus [62]. In this study, González-Domínguez et al. de-
tected significant metabolic impairments associated with energy-pro-
duction pathways, lipid homeostasis, oxidative stress or amino acid
metabolism, in close similarity with findings previously described in
brain, thus demonstrating the involvement of the peripheral system in
AD. In this line, Pan et al. compared plasma and brain metabolomic
profiles from APP × PS1 mice aged between 6 and 18 months us-
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Fig. 2. Metabolomic fingerprints obtained by direct infusion electrospray mass spectrometry (DI-ESI–MS) analysis of serum samples: (a) DI-ESI(+)-MS analysis of aqueous
extracts; (b) DI-ESI(+)-MS analysis of lipophilic extracts; (c) DI-ESI(−)-MS analysis of aqueous extracts; (d) DI-ESI(−)-MS analysis of lipophilic extracts. Reprinted from
González-Domínguez et al. [46] with permission from Springer.
ations in phospholipid and acyl-carnitine homeostasis that follow a
temporal sequence whereby changes in brain metabolites precede
those in blood [63]. On the other hand, the triple transgenic mouse
APP × PS1 × IL4-KO has been proposed as a suitable animal model
to investigate the implication of inflammatory processes in the de-
velopment of AD. MS-fingerprinting of serum samples from these
mice revealed significant changes in circulating levels of different
eicosanoids, amino acids and related compounds, thus evidencing
that depletion of interleukin 4 might potentiate AD pathology in the
APP × PS1 model [64]. To conclude, Lin et al. employed ultra-high
resolution mass spectrometry to identify metabolomic perturbations in
hippocampus [65] and cerebellum [66] from CRND8 transgenic mice;
and similarly to previous works with the APP × PS1 mouse model,
metabolomic profiles exhibited characteristic features associated with
abnormal homeostasis of arachidonic acid leading to the over-produc-
tion of eicosanoids, as well as abnormal metabolism of amino acids,
nucleotides and other metabolites.
3.2. The volatile metabolome: gas chromatography–mass
spectrometry
Nowadays, the coupling GC–MS is still the most suitable alter-
native for the identification of volatile and semi-volatile compounds
in complex biological samples, since it combines high separation
efficiency with sensitive and reproducible mass spectral detection.
This analytical platform has widely been employed for the profiling
of several low molecular weight metabolite classes in AD research,
such as free fatty acids, cholesterol derivatives or neurotransmitters,
among others. However, the application of un-targeted GC-based
metabolomics shows a greater potential to perform a more compre-
hensive characterization of the primary endogenous metabolome (i.e.
amino acids, carbohydrates, organic acids, nucleotides) (Fig. 3). In
this sense, González-Domínguez et al. identified 23 altered metabo-
lites in serum samples from AD patients, some of which had not been
previously described as potential biomarkers of this neurodegener-
ative disorder [67]. Pathway analysis revealed significant perturba
tions in the tricarboxylic acid cycle (TCA), several neurotransmitter
systems, the urea cycle and many other pathways, thus confirming
the utility of this metabolomic approach to monitor disturbances in
central metabolic networks. Exhaled breath has also been proposed
as an interesting biological matrix to investigate AD because blood
changes can be partially transmitted to the alveolar breath through ex-
change in the lung. Volatile organic compounds were extracted by
solid phase microextraction of breath samples from Alzheimer’s dis-
ease, mild cognitive impairment and Parkinson’s disease (PD) pa-
tients, and then were directly analyzed by GC–MS [68]. Thus, in-
creased phenol content was observed in PD samples, but no signifi-
cant differences were found in AD and MCI patients. More recently,
widespread metabolic perturbations were detected in seven regions
from human AD-brains, including those areas traditionally consid-
ered to be less affected by neuronal damage [69]. The most important
findings were an abnormal metabolism of glucose, urea and various
amino acids, which could occur prior to the brain volumetric loss and
therefore could play a pivotal role in early pathogenesis of AD. Sim-
ilarly, GC–MS hippocampal profiles from the SAMP8 mouse model
also showed significant longitudinal alterations in levels of lipids,
amino acids and energy-related metabolites along a 10-months fol-
low-up, from young mice (2 months old) to mature (7 months old)
and finally aged mice (12 months old) [70]. In this line, Hu et al. de-
tected a considerable number of disturbed metabolites in both brain
and plasma samples from the TASTPM transgenic model, in agree-
ment with previously described works [71]. The urinary volatile pro-
file has also been employed to differentiate among three strains of
APP transgenic mice [72]. For this, urine samples were fingerprinted
by headspace GC–MS analysis, which enabled the identification of
several odorants differentially expressed in these AD animal models.
Finally, GC-based metabolomics was applied in a recent study fo-
cused on the investigation of the effects of AβPP transgene on the
Chinese hamster ovary (CHO) cellular line, as well as to confirm the
therapeutic potential of two peroxisome proliferator-activated recep-
tor gamma (PPARγ) agonists [73]. Authors found that extracellular
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Fig. 3. Metabolomic profiles obtained by gas chromatography mass spectrometry (GC–MS) analysis of serum samples: (a) Alzheimer’s disease; (b) healthy controls. Reprinted from
González-Domínguez et al. [67] with permission from Elsevier.
tions, which can be attenuated after treating with these PPARγ ago-
nists.
In summary, it is noteworthy that GC–MS exhibits a great poten-
tial to characterize the perturbations induced by AD in the volatile
metabolome. Thus, despite the inherent drawbacks associated with
this technique, such as the usual need of a derivatization step or the
low sample throughput, a wide range of low molecular weight metabo-
lites can be profiled with excellent sensitivity and reproducibility, in-
cluding amino acids, organic acids, carbohydrates, fatty acids, nu-
cleotides and some others (Fig. 3, Table 1).
3.3. The non-polar metabolome: reversed phase liquid
chromatography–mass spectrometry
In the last years, liquid chromatography has replaced to gas chro-
matography as the most common separation technique in metabolomic
applications because of its wide versatility for resolving various
metabolite classes and higher sample treatment simplicity, without
the need of a derivatization step. Particularly, reversed phase chro-
matography has become the first choice for the profiling of metabo-
lites with medium and low polarity, which account up to 70% of
the human metabolome according to the HMDB [15]. In this con-
text, RP-HPLC-based lipidomics has extensively been proposed for
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opment of AD and other disorders. Sato et al. employed a
metabolomic platform based of HPLC-APCI-MS for the unbiased de-
termination of steroids in plasma samples from AD patients [74]. They
found a considerably reduction in circulating demosterol levels, re-
sults that were additionally validated by subsequent targeted analy-
sis. It has also been demonstrated that the apolipoprotein E (APOE)
genotype has important repercussions on brain and plasma lipidomes
of APOE ε2, ε3, and ε4 knock-in mice, leading to significant alter-
ations in the content of phospholipids, sphingolipids, cholesterol and
triglycerides [75]. In another study, the combination of targeted and
un-targeted lipidomic approaches revealed significant perturbations
in the brain metabolism of endocannabinoids and eicosanoids in the
APP × PS1 mouse model, which could be reversed by inactivating the
monoacylglycerol lipase (MAGL) thus attenuating neuroinflammation
and Aβ production in these transgenic mice [76].
Alternatively, the use of ultra-high-performance liquid chromatog-
raphy has largely emerged in the last decade because of its improved
resolution, sensitivity and reduced analysis time (Fig. 4, Table 1).
Plasma metabolomics has evidenced a close relationship between AD
and the homeostasis of different lipid classes, including bile acids
[77], lyso-phosphatidylcholines and sphingolipid precursors [78], long
chain cholesteryl esters [79], and several phospholipids [80], among
others. More recently, a comprehensive characterization of serum
samples from AD and MCI patients was accomplished, revealing sig-
nificant impairments in the metabolism of acyl-carnitines, lipids po-
tentially implicated in the endocannabinoid system (i.e. oleamide and
monoglycerides), as well as phospholipids and sphingolipids, wherein
the chain length and degree of unsaturation of contained fatty acids
plays a pivotal role [81]. Liang et al. also employed this analyti-
cal platform to differentiate AD, MCI and healthy control subjects
by analyzing serum [82] and saliva samples [83,84]. Re
ceiver operating characteristic (ROC) curves were performed in or-
der to determine the diagnostic effectiveness of the identified discrim-
inant metabolites, and the major contributors to these predictive mod-
els were sphinganine-1-phosphate and 7-ketocholesterol (serum, AD
vs. MCI) [82], sphinganine-1-phosphate, ornithine and phenyl-lac-
tic acid (saliva, AD vs. HC) [83], as well as sphinganine-1-phos-
phate and cytidine (saliva, AD vs. MCI) [84]. The comparative analy-
sis of serum and urine samples also suggested significant lipid dis-
orders mainly affecting the metabolism of lyso-phosphatidylcholines
and sphingolipids, thus confirming the utility of these two non-in-
vasive biofluids to discover AD biomarkers [85]. In another study,
UHPLC-based metabolomics and targeted approaches were combined
to investigate the involvement of an abnormal brain expression of
the polyamine pathway in AD pathogenesis [86]. Tajima et al. also
described the application of RP-UHPLC–MS to perform a global
metabolomic analysis of brain and plasma samples from APP/tau
transgenic mice, thus demonstrating a profound lipid dysregulation in
this model [87]. To conclude, it is noteworthy that this metabolomic
platform has also been proposed for studying the effects of some drugs
on metabolic profiles of several AD animal models. The co-adminis-
tration of huperzine A (HA) and ligustrazine phosphate (LP) showed a
great potential to slow down the progression of AD pathology and reg-
ulate the levels of several potential biomarkers in brain samples from
scopolamine (Sco) induced amnesic rats [88]. The intake of gingeno-
sides, in form of individual species (G-Rg1, G-Rg2, G-Rb1) or as total
gingenoside (TG) extracts, could also revert most of the metabolomic
alterations observed in APP × PS1 and Aβ-lesioned mice [89–91].
Similarly, the treatment with different doses of the herbal Kai-Xin-San
(KXS) significantly improved the cognitive impairment induced in
rats by intraperitoneal injection of D-galactose (D-Gal) and intragas-
trical administration of aluminum chloride [92].
Fig. 4. Metabolomic profiles obtained by liquid chromatography mass spectrometry (LC–MS) analysis of plasma samples: (a) Alzheimer’s disease; (b) healthy controls. Reprinted
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3.4. The hydrophilic metabolome: other strategies
Hydrophilic metabolites are usually not retained in reversed phase
LC columns, and only thermally stable compounds can be profiled by
GC–MS after a time-consuming derivatization step. For this reason,
complementary methodologies are necessary to expand the analytical
coverage of MS-based techniques towards the polar metabolome. Dif-
ferent strategies have been proposed with the aim to improve the re-
solving power of RP-LC for hydrophilic compound analysis. In this
sense, it should be noted that various manufacturers have developed
novel RP columns with superior polar compound retention. Myint et
al. optimized a metabolomic approach for the quantitative profiling of
cationic metabolites in human CSF samples using a mixed-functional
capillary column with RP and cation exchange resins [93]. Similarly,
the combination of genomics, transcriptomics and UHPLC-based
metabolomics in a Zorbax SB-Aq column enabled the elucidation of
a deep deregulation of purine metabolism in entorhinal cortex of AD
patients at different stages of disease [94]. Another alternative is the
use of ion pairing reagents in order to increase the hydrophobicity, and
consequently the retention, of polar metabolites. Kaddurah-Daouk et
al. employed a metabolomic platform based on liquid chromatography
with pentane sulfonic acid as ion-pairing agent and subsequent elec-
trochemical array detection (ECA) to monitor redox-active metabo-
lites in CSF from AD and MCI patients [95,96]. This technique en-
abled the detection of numerous metabolites involved in the homeosta-
sis of tryptophan, tyrosine, phenylalanine, methionine and purine, thus
revealing significant perturbations in pathways associated with neu-
rotransmission, oxidative stress and one-carbon metabolism, among
others. A third option is the derivatization of hydrophilic metabolites,
which in addition to improve retention in RP columns can also help to
increase sensitivity and isomer separation efficiency. In this context,
chiral metabolomics based on the labeling with optically-active de-
rivatization reagents and subsequent precursor ion scan chromatogra-
phy of the derivatives has been proposed for the identification of enan-
tiomeric amines and carboxyls as biomarker candidates for AD diag-
nosis [97]. Alternatively, dansylation of salivary and urinary metabo-
lites has also been described for the investigation of metabolic abnor-
malities associated with AD pathogenesis [98,99].
Hydrophilic interaction liquid chromatography (HILIC) is a rel-
atively recent mode of separation that has gained a great popular-
ity in the last years for the profiling of polar metabolites. This tech-
nique combines polar columns and mobile phases normally used in
RP separations, with gradients starting at high organic concentrations.
Under these conditions, hydrophilic compounds can be retained via
partitioning onto a water-rich layer that is partially immobilized on
the surface of the stationary phase, and then eluted by increasing the
eluent water content. Thus, in contrast to conventional normal phase
chromatography, HILIC shows a great compatibility with MS detec-
tion due to the high organic-content of mobile phases, which facili-
tates solvent evaporation and consequently improves ionization effi-
ciency. Some preliminary studies demonstrated the potential of this
analytical platform to differentiate AD patients and HC subjects by
fingerprinting the polar metabolome of brain [100] and plasma sam-
ples [101]. However, despite a great number of ions were detected
in both biological matrices, and statistical models built with these
data were able to classify subjects with excellent accuracy, discrim-
inant signals were not identified. More recently, HILIC-MS plasma
metabolomics highlighted the central role of altered homeostasis of
polyamines and arginine in the onset of AD and its progression from
MCI [102], in line with previous studies [47,86]. In another work,
Tang et al. employed this metabolomic approach for analyzing hy-
drophilic metabolites in urine samples from CRND8 transgenic mice
[103]. Significant changes were observed in urinary levels of multiple
amino acids, fatty acids, nucleotides and other metabolites, thus evi-
dencing impairments in the mitochondrial energy metabolism, trypto-
phan homeostasis and the induction of oxidative stress, among other
pathological hallmarks.
Finally, the coupling CE-MS has also been described for the char-
acterization of perturbations in the polar metabolome associated with
AD pathogenesis in different biological fluids. Ibáñez et al. employed
this separation technique to monitor metabolomic alterations related
to AD progression in CSF from subjects with different cognitive sta-
tus, including AD patients, MCI patients that progressed to AD within
2 years, MCI patients that remained stable after this follow-up pe-
riod, and patients with subjective cognitive impairment (SCI) [104].
Thereby, a panel of LMW-hydrophilic metabolites was identified as
potential biomarkers of disease progression, including choline, va-
line, a tripeptide, dimethylarginine, creatine, serine, arginine, suberyl-
glycine, carnitine and histidine. Similarly, the analysis of serum sam-
ples revealed a close relationship between the development of AD and
multiple pathological processes, such as oxidative stress, defects in en-
ergy metabolism, or vascular risk factors, among others [105]. More-
over, the combined CE-fingerprinting of serum and saliva samples en-
abled differentiating between different neurodegenerative dementias,
including AD, frontotemporal lobe dementia (FTLD) and Lewy body
disease (LBD) [106].
3.5. Comprehensive metabolomics: multi-platform approaches
As a consequence of the selectivity of most of the previously de-
scribed analytical techniques towards the profiling of specific metabo-
lite classes, the use of metabolomic multi-platforms based on the com-
bination of complementary tools is emerging in the last years as the
most suitable option to achieve a comprehensive characterization of
metabolite alterations underlying to complex phenotypes. With re-
gards to AD research, two strategies have been previously described
to this end, (i) the combination of reversed-phase liquid chromatogra-
phy and gas chromatography; and (ii) the combination of orthogonal
reversed-phase and hydrophilic interaction liquid chromatography.
3.5.1. The combination of reversed-phase liquid chromatography
and gas chromatography coupled to mass spectrometry
The first multi-metabolomic investigation of AD pathogenesis was
described by Orešič et al. in 2011 [107]. In this prospective study,
serum samples from AD, MCI and control subjects were subjected to
lipidomic analysis by RP-UHPLC–MS and metabolomic analysis by
GC × GC–MS. At the baseline, AD patients showed reduced circulat-
ing levels of plasmalogens, phosphatidylcholines, sphingomyelins and
sterols; while 2,4-dihydroxybutanoic acid was identified as the most
important predictor of dementia progression in the follow-up. More
recently, two panels of potential diagnostic plasma markers were able
to discriminate AD and MCI patients from normal controls, compris-
ing metabolites involved in diverse biochemical pathways, such as en-
ergy metabolism, amino acid homeostasis or one-carbon metabolism,
among others [108]. Complementarily, this metabolomic multi-plat-
form has also been proposed for profiling cerebrospinal fluid sam-
ples. Czech et al. found numerous metabolite alterations that could
be directly associated with perturbations in brain metabolism, prin-
cipally in several neurotransmitter systems [109]. Then, ROC analy-
sis was performed in order to evaluate the diagnostic performance
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Thereby, it was observed that the combination of CSF levels of cor-
tisol, uridine, cysteine and other amino acids provide predictive mod-
els with sensitivity and specificity above 80%. In this line, another
study compared the accuracy of metabolomics to discriminate AD pa-
tients from healthy controls with that provided by traditional patholog-
ical markers (i.e. Aβ and tau) [110]. Two unidentified metabolic fea-
tures showed promising capabilities as potential diagnostic markers,
but further confirmatory and validation studies are required.
On the other hand, the combination of GC–MS and RP-UH-
PLC–MS has also been described for the comprehensive characteri-
zation of metabolic abnormalities induced in transgenic animal mod-
els of AD (Fig. 5). In order to complement and confirm prelimi-
nary findings obtained by DIMS analysis [59–62] (Section 4.1.2),
González-Domínguez et al. employed this metabolomic multi-plat-
form to investigate multiple biological compartments from the
APP × PS1 mouse model. Numerous alterations were observed in the
homeostasis of phospholipids, sphingolipids, fatty acids, cholesterol,
acyl-carnitines, energy-related metabolites, amino acids, nucleotides
and some other compounds affecting the whole organism, including
serum [111], brain [112], metabolically active organs [113] and organs
involved in the immune function [114], in line with previous find-
ings. Similarly, Trushina et al. demonstrated that many of these im-
pairments can also be detected in hippocampus from other transgenic
animals [115].
3.5.2. The combination of reversed-phase and hydrophilic
interaction liquid chromatography coupled to mass spectrometry
A second alternative to maximize metabolomic coverage is the
combination of orthogonal RP and HILIC separation prior to the
MS detection (Table 1). This strategy has been employed to ana-
lyze CSF samples from four diagnostic groups related to AD pro-
gression: healthy control subjects, stable MCI patients, MCI sub-
jects who developed AD after a follow-up period of 2 years, and
a group of patients with AD [116]. Significant alterations were ob-
served in levels of 17 metabolites along the progression of disease
among the four study groups, in line with previous findings obtained
by CE-MS analysis [104]. In another study, Armirotti et al. optimized
a metabolomic approach based on the extraction of plasma samples
using a variation of the classical three-phase Bligh-Dyer procedure
and subsequent analysis by RP/HILIC-UHPLC–MS [117]. The appli-
cation of this metabolomic multi-platform to plasma samples from the
MCI/AD Italian prevention project evidenced a clear separation be-
tween MCI and control subjects, but surprisingly no differentiation
was observed between AD patients and controls. The complementary
analysis of plasma and CSF samples was also proposed with the aim
to perform a more exhaustive investigation of pathological mecha-
nisms underlying to AD [118]. Changes in more than 150 metabo-
lites were detected, which could be related to 23 and 20 altered path-
ways in plasma and CSF, respectively. To conclude, the potential of
combining orthogonal separation mechanisms has also been recently
Fig. 5. Overview of metabolic changes detected in APP/PS1 transgenic mice after the application of a metabolomic multi-platform based on the combination of GC–MS and UH-
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demonstrated by analyzing frontal cortex homogenates from AD and
control subjects [119]. Authors found significant impairments in the
homeostasis of phospholipids and six metabolic pathways of the cen-
tral metabolism, and in conjunction with MS imaging confirmed a
marked dysregulation of the mitochondrial aspartate metabolism.
4. Critical discussion of existing metabolomic data: translating
analytical results into the clinical practice
The neuropathology of Alzheimer’s disease has traditionally been
associated with the formation of senile plaques and neurofibrillary tan-
gles on brain, principally in cortical and hippocampal regions, leading
to a gradual loss of neurons and synapses. However, there is great ev-
idence supporting that this cognitive dysfunction may have a complex
and heterogeneous origin. In this sense, it is noteworthy that impaired
metabolism is increasingly being recognized as a pivotal player in the
development of diseases usually not considered as “metabolic disor-
ders”, including cancer, neurodegenerative disorders and many oth-
ers. Thereby, the application of metabolomic technologies has largely
emerged in the last years with the aim to identify the metabolic sig-
nature of diseases in a comprehensive manner. Considering data pre-
sented in Table 1, it seems clear that multiple metabolic alterations
could be involved in the pathogenesis and progression of Alzheimer’s
disease. Particularly, disturbed lipid metabolism has been proven to
be a key hallmark of Alzheimer’s disease, as reflected in abnormal
levels of various lipid classes. Numerous metabolomic studies have
previously reported significant changes in the content of phospho-
lipids, sphingolipids and related catabolic metabolites in several bio-
logical samples, thus evidencing the occurrence of membrane destabi-
lization processes. Similarly, cholesterol homeostasis also plays a piv-
otal role in AD pathogenesis, probably as a consequence of the im-
plication of this compound on the formation of neuronal lipid rafts.
Moreover, hyperlipidemia has been described as a very important risk
factor for AD development, which is finally reflected in increased
circulating levels of triglycerides and other neutral lipids. As would
be expected, metabolomics-based investigations also revealed signif-
icant impairments in the biosynthesis of metabolites related to multi-
ple neurotransmitter systems, such as the cholinergic, glutamatergic,
GABAergic, serotonergic or dopaminergic systems. In addition, exist-
ing metabolomic data has also demonstrated profound impairments in
numerous pathways related to energy metabolism, including glycoly-
sis, the tricarboxylic acid cycle, β-oxidation of lipids, gluconeogenesis
and ketogenesis, among others. This altered metabolic rate is usually
accompanied by enhanced oxidative stress, which results in decreased
levels of antioxidant compounds and increased markers of protein,
lipid, and nucleic acid oxidation. Besides these most common meta-
bolic alterations, there is also evidence of the involvement of other
central pathways in AD pathogenesis, such as the urea cycle or the me-
tabolism of purines, polyamines and bile acids among other metabo-
lites, thus demonstrating the multifactorial character of this neurode-
generative disorder.
Although most of this previously published metabolomic research
on Alzheimer’s disease is focused on the elucidation of pathological
mechanisms potentially related to disease etiology, some authors also
investigated the utility of these discriminant metabolites as diagnostic
biomarkers. In these studies, receiver operating characteristic (ROC)
curve analysis is usually performed in order to validate the sensitiv-
ity and specificity of these candidate biomarkers. Czech et al. found
that several combinations of three to five CSF metabolites could be
used to discriminate AD patients from healthy control volunteers, but
without any utility in the clinical practice since the statistical perfor-
mance did not exceed to that provided by classical protein markers
(i.e. Aβ-42 and tau) [109]. Conversely, in a more recent study it was
demonstrated that GC-based metabolomic profiles provide similar dis-
criminating potential to that showed by traditional pathological mark-
ers [110]. In this line, Laakso et al. reported that “the composition of
CSF contains enough information of the neurological state of a given
patient with a given dementia to be diagnosed with extremely high ac-
curacy” [37]. Complementarily, the investigation of peripheral biolog-
ical samples has also been proposed with the aim to identify simpler
and cheaper biomarkers translatable to the clinical practice, including
blood [58,74,108], saliva [83] and urine [85]. On the other hand, it
is noteworthy that metabolomic data has also been employed to build
predictive models able to monitor the progression of AD in the fol-
low-up and to predict the conversion of mild cognitive impairment
into Alzheimer’s disease [80,82,84,107].
Anyway, none of these potential biomarkers identified through
metabolomic approaches have reached the clinic because of various
reasons. First, non-targeted metabolomics may produce conflicting re-
sults due to the lack of standardized protocols for sampling, analysis
and data processing, as shown in Table 1. Furthermore, low population
sizes usually employed in these studies reduce the statistical signifi-
cance of findings obtained, so these preliminary data must be validated
in large-scale human populations using targeted and quantitative ana-
lytical platforms before to be considered as clinical markers. Finally, it
would be also interesting to extend these metabolomic investigations
to other types of dementia with the aim to evaluate the specificity of
these putative biomarkers against other neurodegenerative disorders.
5. Conclusions & perspectives
Metabolomics has demonstrated a great potential to unravel the
complex patho-biochemistry underlying to Alzheimer’s disease, as
summarized in the present review article. Various biological samples
have been investigated, from both aged human cohorts and transgenic
animal models, in order to get a deeper understanding of this disor-
der, including brain, cerebrospinal fluid, peripheral organs (e.g. liver,
kidney, spleen, thymus), and several other biofluids such as plasma,
serum, urine or saliva. Thereby, AD pathogenesis has been associated
with widespread perturbations affecting multiple central metabolic
pathways, including abnormal homeostasis of numerous lipid classes
(e.g. phospholipids, sphingolipids, cholesterol, eicosanoids, acyl-car-
nitines), energy-related failures, disrupted neurotransmission, oxida-
tive stress, and many others (Table 1). However, a major constraint of
most of these previously published metabolomic studies is the lack of
a reliable validation step of discriminant metabolites detected in the
discovery phase using larger cohorts of patients. For this purpose, the
inclusion of other types of dementias could be of great interest with the
aim to evaluate the specificity of these candidate biomarkers, which
has scarcely been considered to date [27,68,106].
The application of a wide variety of metabolomic approaches has
been described in AD research. Nuclear magnetic resonance can be
employed for high-throughput profiling of some important endoge-
nous metabolites, but its reduced sensitivity considerably hinders the
analysis of complex samples. Alternatively, platforms based on di-
rect mass spectrometry analysis (i.e. DI-MS, FI-MS) stand out as suit-
able tools for fast and non-discriminant metabolomic screening. On
the other hand, the coupling of sensitive MS detection with orthogonal
separation methods allows reducing the complexity of metabolomic
profiles by focusing on specific metabolite classes. Reversed-phase
liquid chromatography is nowadays the main workhorse in
metabolomics because of its excellent performance for fingerprint-
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spectrometry provides high sensitivity and resolving power for the de-
termination of primary low molecular weight metabolites (i.e. amino
acids, organic acids, carbohydrates, amines). Moreover, other analyt-
ical techniques have also been proposed with the aim to expand the
metabolomic coverage towards hydrophilic compounds without the
recourse of a derivatization step, such as hydrophilic interaction liq-
uid chromatography and capillary electrophoresis. As a consequence
of the inherent analytical bias introduced by these techniques, it is
noteworthy that none single platform is able to capture the entire
metabolome. Thus, the combination of complementary approaches is
emerging in recent years as the most suitable strategy to maximize
the coverage of the AD-related metabolome. Basically, two differ-
ent multi-platforms have been previously proposed in AD research:
(i) RP-LC/GC–MS [107–115], and (ii) RP-LC/HILIC-MS [116–119].
However, metabolomic tools based on direct MS analysis have also
gained a great popularity because of its high-throughput capability and
wide metabolome coverage, which allows analyzing hundreds of sam-
ples per day in a comprehensive manner [44]. Thus, in the author’s
opinion, the combination of fast DIMS-based screening and subse-
quent fingerprinting via orthogonal hyphenated approaches could be
the most suitable strategy with the aim to accomplish a global charac-
terization of the human metabolome. DIMS analysis can be employed
to carry out a preliminary investigation in order to visualize general
trends and detect discriminant patterns among the study groups. Fur-
thermore, its combination with ion mobility instruments could be an
interesting alternative to allow the separation of isomers and increase
the screening specificity through the measurement of collision cross
section (CCS) values [120]. Then, low polarity compounds can be pro-
filed by RP-UHPLC–MS. To date, most of the previously published
UHPLC–MS-based studies have almost exclusively been performed
via interfacing with electrospray ionization, but it should be noted
that other ionization sources such as APCI and APPI can also provide
complementary ionization capabilities to expand metabolomic cover-
age towards less polar compounds [47,59,74]. Furthermore, another
important concern to be solved in order to increase the performance
of this metabolomic platform is the improvement of existing spectral
libraries and databases in order to facilitate the annotation of discrimi-
nant compounds [16]. Finally, several analytical techniques can be ap-
plied to monitor alterations in the hydrophilic metabolome. The cou-
plings of HILIC and CE with mass spectrometry are relatively recent
introduced tools in the metabolomic area for direct fingerprinting of
polar and ionic compounds. However, despite the need of a previous
derivatization step, GC–MS is still the most powerful choice for ana-
lyzing the LMW-metabolome due to its high sensitivity and separation
efficiency, especially when multidimensional GC × GC is employed,
as well as simpler peak identification through spectral libraries.
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